Tapio Nousiainen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tapio Nousiainen has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Esa Jantunen
Department of Medicine, Kuopio University Hospital, Kuopio, Finland
19 shared publications J. Hartikainen
From the Department of Medicine, Kuopio University Hospital, Kuopio, Finland
6 shared publicationsE. Jantunen
From the Department of Medicine, Kuopio University Hospital, Kuopio, Finland
5 shared publicationsE. Vanninen
From the Department of Clinical Physiology and Nuclear Medicine, Kuopio University Hospital, Kuopio, Finland
5 shared publicationsJ. Remes
From the Department of Medicine, Satakunta Central Hospital, Pori, Finland
5 shared publicationsA. Rantala
From the Department of Medicine, Kuopio University Hospital, Kuopio, Finland
4 shared publications
Latest Publications
- 1 January 2007
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 48 (1) , 190-191
Secondary acute promyelocytic leukemia: An increasingly common entity
- 1 January 2007
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 48 (1) , 190-191
Secondary acute promyelocytic leukemia: An increasingly common entity
- 1 December 2004
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 45 (12) , 2485-2489
Autologous Stem Cell Transplantation in Patients with Primary Amyloidosis: A Nation-wide Survey
Due to poor prognosis with conventional therapy, high-dose therapy (HDT) with autologous stem cell transplantation (ASCT) is considered for treatment in patients with primary amyloidosis (AL). Only single centre series are available on the feasibility and efficacy of this approach. Altogether 20 AL patients (11 males, 9 females, median age 54 years) were included in HDT protocols in 5 Finnish transplant centres between 1997 and 2003. Twelve patients were mobilized with granulocyte colony-stimulating factor (G-CSF) alone and 8 patients with a combination of cyclophosphamide and G-CSF. Sixteen patients (80%) went on to high-dose melphalan. Early transplant-related mortality was 25%. Nine out of 11 evaluable patients showed improvement or stabilization of AL. The overall survival of the transplanted patients is 69% (median follow-up 13 months). After a median follow-up of 26 months for the living patients, only 2 patients (18%) have shown progression of AL. This retrospective nation-wide analysis shows that HDT with ASCT leads to improvement or stabilization of AL in the majority of the patients who survive the immediate posttransplant period. A randomized multicentre trial is needed to show whether ASCT is superior to conventional therapy in patients with AL.
- 1 December 2004
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 45 (12) , 2485-2489
Autologous Stem Cell Transplantation in Patients with Primary Amyloidosis: A Nation-wide Survey
Due to poor prognosis with conventional therapy, high-dose therapy (HDT) with autologous stem cell transplantation (ASCT) is considered for treatment in patients with primary amyloidosis (AL). Only single centre series are available on the feasibility and efficacy of this approach. Altogether 20 AL patients (11 males, 9 females, median age 54 years) were included in HDT protocols in 5 Finnish transplant centres between 1997 and 2003. Twelve patients were mobilized with granulocyte colony-stimulating factor (G-CSF) alone and 8 patients with a combination of cyclophosphamide and G-CSF. Sixteen patients (80%) went on to high-dose melphalan. Early transplant-related mortality was 25%. Nine out of 11 evaluable patients showed improvement or stabilization of AL. The overall survival of the transplanted patients is 69% (median follow-up 13 months). After a median follow-up of 26 months for the living patients, only 2 patients (18%) have shown progression of AL. This retrospective nation-wide analysis shows that HDT with ASCT leads to improvement or stabilization of AL in the majority of the patients who survive the immediate posttransplant period. A randomized multicentre trial is needed to show whether ASCT is superior to conventional therapy in patients with AL.
- 1 January 2003
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 44 (5) , 883-885
Multiple Complete Remissions in a Patient with Acute Myeloid Leukemia (M4eo) with Low-dose Cytosine Arabinoside and All- trans Retinoic Acid
A 54-year-old female with acute myeloid leukemia (AML) (FAB M4eo) was treated at second relapse with a combination of low-dose cytosine arabinoside (LDAraC) (20 mg b.i.d. subcutaneously) and all- trans retinoic acid (ATRA) (45 mg/m 2 /d orally) on days 1-10. The patient achieved a complete hematological remission after the first cycle and was consolidated with three similar cycles at four-week intervals. Subsequently, the patient relapsed several times. Altogether seven complete hematological remissions including some cytogenetic remissions were induced with the same regimen. The patient survived 81 months after the start with LDAraC-ATRA regimen. This low-toxicity regimen may be useful in some patients with poor-risk AML.
- 1 January 2003
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 44 (5) , 883-885
Multiple Complete Remissions in a Patient with Acute Myeloid Leukemia (M4eo) with Low-dose Cytosine Arabinoside and All- trans Retinoic Acid
A 54-year-old female with acute myeloid leukemia (AML) (FAB M4eo) was treated at second relapse with a combination of low-dose cytosine arabinoside (LDAraC) (20 mg b.i.d. subcutaneously) and all- trans retinoic acid (ATRA) (45 mg/m 2 /d orally) on days 1-10. The patient achieved a complete hematological remission after the first cycle and was consolidated with three similar cycles at four-week intervals. Subsequently, the patient relapsed several times. Altogether seven complete hematological remissions including some cytogenetic remissions were induced with the same regimen. The patient survived 81 months after the start with LDAraC-ATRA regimen. This low-toxicity regimen may be useful in some patients with poor-risk AML.
- Open Access
- 7 June 2002
- Published by Springer Nature in British Journal of Cancer
- Vol. 86 (11) , 1697-1700
Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients
Thirty adult patients with non-Hodgkin's lymphoma were studied to evaluate prospectively the significance of early decline in left ventricular ejection fraction after low cumulative doxorubicin dose (200 mg x m(-2)) in predicting the later impairment of left ventricular function. Cardiac function was monitored with radionuclide ventriculography at baseline and after cumulative doxorubicin doses of 200, 400 and 500 mg x m(-2). Cardiotoxicity was defined as a decrease in left ventricular ejection fraction of more than 10% units to a final left ventricular ejection fraction < or =50%. Twenty-eight patients received doxorubicin > or =400 mg x m(-2) and were evaluable for cardiotoxicity. Clinical heart failure developed in two patients (7%) after a cumulative doxorubicin dose of 500 mg m(-2). Left ventricular ejection fraction decreased more than 10% absolute ejection fraction units to a final left ventricular ejection fraction < or =50% in 10 patients (36%). Left ventricular ejection fraction decreased from 56+/-1.5% to 53.6+/-1.5% (P=0.016) in patients with no cardiotoxicity, and from 60.8+/-2.4% to 41.8+/-2.0% (P<0.001) in patients with cardiotoxicity. For patients who developed cardiotoxicity, the fall in left ventricular ejection fraction after a cumulative doxorubicin dose of only 200 mg x m(-2) was highly significant (left ventricular ejection fraction 49.7+/-1.8%, P=0.001 vs baseline). In receiver operator characteristic analysis, the area under the curve for the decrease in left ventricular ejection fraction at a cumulative doxorubicin dose of 200 mg x m(-2) for predicting cardiotoxicity in all patients was 0.858. The decrease in left ventricular ejection fraction of more than 4% units after a cumulative doxorubicin dose of 200 mg x m(-2) had a 90% sensitivity and 72% specificity for predicting later cardiotoxicity. Our results show that the significant impairment of left ventricular function during doxorubicin therapy can be predicted early, already at low cumulative doxorubicin doses. This finding may be of value in identifying patients at high or low risk for the development of anthracycline cardiotoxicity.
- 7 June 2002
- Published by Springer Nature in British Journal of Cancer
- Vol. 86 (11) , 1697-1700
Open AccessEarly decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients
Thirty adult patients with non-Hodgkin's lymphoma were studied to evaluate prospectively the significance of early decline in left ventricular ejection fraction after low cumulative doxorubicin dose (200 mg x m(-2)) in predicting the later impairment of left ventricular function. Cardiac function was monitored with radionuclide ventriculography at baseline and after cumulative doxorubicin doses of 200, 400 and 500 mg x m(-2). Cardiotoxicity was defined as a decrease in left ventricular ejection fraction of more than 10% units to a final left ventricular ejection fraction < or =50%. Twenty-eight patients received doxorubicin > or =400 mg x m(-2) and were evaluable for cardiotoxicity. Clinical heart failure developed in two patients (7%) after a cumulative doxorubicin dose of 500 mg m(-2). Left ventricular ejection fraction decreased more than 10% absolute ejection fraction units to a final left ventricular ejection fraction < or =50% in 10 patients (36%). Left ventricular ejection fraction decreased from 56+/-1.5% to 53.6+/-1.5% (P=0.016) in patients with no cardiotoxicity, and from 60.8+/-2.4% to 41.8+/-2.0% (P<0.001) in patients with cardiotoxicity. For patients who developed cardiotoxicity, the fall in left ventricular ejection fraction after a cumulative doxorubicin dose of only 200 mg x m(-2) was highly significant (left ventricular ejection fraction 49.7+/-1.8%, P=0.001 vs baseline). In receiver operator characteristic analysis, the area under the curve for the decrease in left ventricular ejection fraction at a cumulative doxorubicin dose of 200 mg x m(-2) for predicting cardiotoxicity in all patients was 0.858. The decrease in left ventricular ejection fraction of more than 4% units after a cumulative doxorubicin dose of 200 mg x m(-2) had a 90% sensitivity and 72% specificity for predicting later cardiotoxicity. Our results show that the significant impairment of left ventricular function during doxorubicin therapy can be predicted early, already at low cumulative doxorubicin doses. This finding may be of value in identifying patients at high or low risk for the development of anthracycline cardiotoxicity.
- Open Access
- 3 March 2002
- Published by Wiley in Journal of Internal Medicine
- Vol. 251 (3) , 228-234
Natriuretic peptides during the development of doxorubicin‐induced left ventricular diastolic dysfunction
Nousiainen T, Vanninen E, Jantunen E, Puustinen J, Remes J, Rantala A, Vuolteenaho O, Hartikainen J (Kuopio University Hospital, Kuopio; Satakunta Central Hospital, Pori; University of Oulu, Oulu, Finland). Natriuretic peptides during the development of doxorubicin‐induced left ventricular diastolic dysfunction. J Intern Med 2002; 251: 228–234. Objectives. To investigate changes in plasma atrial natriuretic peptide (ANP), N‐terminal pro‐atrial natriuretic peptide (NT‐pro‐ANP) and brain natriuretic peptide (BNP) during the development of doxorubicin‐induced left ventricular systolic and diastolic dysfunction as measured by echocardiography (ECHO). Design. Prospective study. Setting. University hospital. Subjects. Twenty‐eight adult patients with non‐Hodgkin’s lymphoma, who received doxorubicin to the cumulative dose of 400–500 mg m−2. Main outcome measures. The relationship between plasma natriuretic peptides and systolic and diastolic ECHO indices after the cumulative doxorubicin doses of 200, 400 and 500 mg m−2. Results. Left ventricular ejection fraction (LVEF, by 2D ECHO) decreased from 58 ± 1.7 to 52.5 ± 1.3% (P=0.036) and fractional shortening (FS) from 34.6 ± 1.4 to 27.8 ± 0.9% (P=0.002). Peak E wave velocity decreased from 63.3 ± 3.2 to 51.3 ± 2.6 cm s−1 (P=0.008) resulting in a statistically nonsignificant decrease in E/A ratio from 1.08 ± 0.01 to 0.85 ± 0.07. A significant decrease was observed in the percentage of left ventricular filling during the 1/3 of diastole (1/3FF) from 42.2 ± 1.7 to 36.5 ± 2.0% (P < 0.001). LV end systolic diameter increased from 32 ± 1 to 38 ± 1 mm (P=0.011), whereas left atrial (LA) diameter remained unchanged. Peak filling rate decreased from 4.4 ± 0.2 to 4.0 ± 0.2 stroke volume s−1 (SV s−1) (ns). Plasma levels of ANP increased from 16.4 ± 1.3 to 22.7 ± 2.4 pmol L−1 (P=0.002), NT‐pro‐ANP from 288 ± 22 to 380 ± 42 pmol L−1 (P=0.019) and BNP from 3.3 ± 0.4 to 8.5 ± 2.0 pmol L−1 (P=0.020). There was a significant inverse correlation between the decrease in FS and the increases in plasma NT‐pro‐ANP (r=−0.524, P=0.018) and plasma BNP (r=0.462, P=0.04) and between the decrease in PFR and the increases in plasma ANP (r=−0.457, P=0.043) and plasma NT‐pro‐ANP (r=−0.478, P=0.033). Furthermore, after doxorubicin therapy, significant inverse correlations were observed between E/A ratio and plasma ANP (r=−0.535, P=0.008), between E/A ratio and plasma NT‐pro‐ANP (r=−0.432, P=0.04) and between E/A ratio and plasma BNP (r=−0.557, P=0.006) as well as between 1/3FF and plasma BNP (r=−0.493, P=0.017). There was also a trend for correlation between LA diameter and plasma BNP (r=0.395, P=0.062) and peak E wave velocity and plasma BNP (r=−0.414, P=0.05), respectively. However, no significant correlations were observed between any of the systolic parameters and natriuretic peptide levels. Conclusions. The results of this prospective study show that during the evolution of doxorubicin‐induced LV dysfunction the secretion of natriuretic peptides is more closely associated with the impairment of left ventricular diastolic filling than with the deterioration of LV systolic function.
- 3 March 2002
- Published by Wiley in Journal of Internal Medicine
- Vol. 251 (3) , 228-234
Open AccessNatriuretic peptides during the development of doxorubicin‐induced left ventricular diastolic dysfunction
Nousiainen T, Vanninen E, Jantunen E, Puustinen J, Remes J, Rantala A, Vuolteenaho O, Hartikainen J (Kuopio University Hospital, Kuopio; Satakunta Central Hospital, Pori; University of Oulu, Oulu, Finland). Natriuretic peptides during the development of doxorubicin‐induced left ventricular diastolic dysfunction. J Intern Med 2002; 251: 228–234. Objectives. To investigate changes in plasma atrial natriuretic peptide (ANP), N‐terminal pro‐atrial natriuretic peptide (NT‐pro‐ANP) and brain natriuretic peptide (BNP) during the development of doxorubicin‐induced left ventricular systolic and diastolic dysfunction as measured by echocardiography (ECHO). Design. Prospective study. Setting. University hospital. Subjects. Twenty‐eight adult patients with non‐Hodgkin’s lymphoma, who received doxorubicin to the cumulative dose of 400–500 mg m−2. Main outcome measures. The relationship between plasma natriuretic peptides and systolic and diastolic ECHO indices after the cumulative doxorubicin doses of 200, 400 and 500 mg m−2. Results. Left ventricular ejection fraction (LVEF, by 2D ECHO) decreased from 58 ± 1.7 to 52.5 ± 1.3% (P=0.036) and fractional shortening (FS) from 34.6 ± 1.4 to 27.8 ± 0.9% (P=0.002). Peak E wave velocity decreased from 63.3 ± 3.2 to 51.3 ± 2.6 cm s−1 (P=0.008) resulting in a statistically nonsignificant decrease in E/A ratio from 1.08 ± 0.01 to 0.85 ± 0.07. A significant decrease was observed in the percentage of left ventricular filling during the 1/3 of diastole (1/3FF) from 42.2 ± 1.7 to 36.5 ± 2.0% (P < 0.001). LV end systolic diameter increased from 32 ± 1 to 38 ± 1 mm (P=0.011), whereas left atrial (LA) diameter remained unchanged. Peak filling rate decreased from 4.4 ± 0.2 to 4.0 ± 0.2 stroke volume s−1 (SV s−1) (ns). Plasma levels of ANP increased from 16.4 ± 1.3 to 22.7 ± 2.4 pmol L−1 (P=0.002), NT‐pro‐ANP from 288 ± 22 to 380 ± 42 pmol L−1 (P=0.019) and BNP from 3.3 ± 0.4 to 8.5 ± 2.0 pmol L−1 (P=0.020). There was a significant inverse correlation between the decrease in FS and the increases in plasma NT‐pro‐ANP (r=−0.524, P=0.018) and plasma BNP (r=0.462, P=0.04) and between the decrease in PFR and the increases in plasma ANP (r=−0.457, P=0.043) and plasma NT‐pro‐ANP (r=−0.478, P=0.033). Furthermore, after doxorubicin therapy, significant inverse correlations were observed between E/A ratio and plasma ANP (r=−0.535, P=0.008), between E/A ratio and plasma NT‐pro‐ANP (r=−0.432, P=0.04) and between E/A ratio and plasma BNP (r=−0.557, P=0.006) as well as between 1/3FF and plasma BNP (r=−0.493, P=0.017). There was also a trend for correlation between LA diameter and plasma BNP (r=0.395, P=0.062) and peak E wave velocity and plasma BNP (r=−0.414, P=0.05), respectively. However, no significant correlations were observed between any of the systolic parameters and natriuretic peptide levels. Conclusions. The results of this prospective study show that during the evolution of doxorubicin‐induced LV dysfunction the secretion of natriuretic peptides is more closely associated with the impairment of left ventricular diastolic filling than with the deterioration of LV systolic function.
- 1 January 2002
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 43 (10) , 1961-1965
A Pilot Study on Feasibility and Efficacy of Amifostine Preceding High-dose Melphalan with Autologous Stem Cell Support in Myeloma Patients
To evaluate feasibility and potential efficacy of amifostine (AMI) in the prevention of toxicities associated with high-dose melphalan (MEL), ten myeloma patients received AMI 910 mg/m2 in 15 min infusion preceding MEL 200 mg/m2 followed by stem cell infusion (AMI group). Hematologic and extra-hematologic toxicities as well as the need for supportive care observed in the AMI group were compared with ten myeloma patients treated in an identical protocol but without AMI. Hypotension was the most important adverse event of AMI infusion. No differences were observed in the time of engraftment between the AMI group and the control group neither was there any difference in the need for supportive care. Oral mucositis grade >2 was observed in 30% of the patients in both groups. Diarrhea grade >2 occurred only in two AMI patients but in five control patients. AMI preceding high-dose MEL is feasible, although adverse events are observed in some patients. Whether AMI could reduce the gastrointestinal toxicity associated with high-dose MEL can be reliably assessed only in prospective randomized trials.
- 1 January 2002
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 43 (10) , 1961-1965
A Pilot Study on Feasibility and Efficacy of Amifostine Preceding High-dose Melphalan with Autologous Stem Cell Support in Myeloma Patients
To evaluate feasibility and potential efficacy of amifostine (AMI) in the prevention of toxicities associated with high-dose melphalan (MEL), ten myeloma patients received AMI 910 mg/m2 in 15 min infusion preceding MEL 200 mg/m2 followed by stem cell infusion (AMI group). Hematologic and extra-hematologic toxicities as well as the need for supportive care observed in the AMI group were compared with ten myeloma patients treated in an identical protocol but without AMI. Hypotension was the most important adverse event of AMI infusion. No differences were observed in the time of engraftment between the AMI group and the control group neither was there any difference in the need for supportive care. Oral mucositis grade >2 was observed in 30% of the patients in both groups. Diarrhea grade >2 occurred only in two AMI patients but in five control patients. AMI preceding high-dose MEL is feasible, although adverse events are observed in some patients. Whether AMI could reduce the gastrointestinal toxicity associated with high-dose MEL can be reliably assessed only in prospective randomized trials.
- 1 January 2002
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 43 (9) , 1807-1811
Concomitant Impairment of Left Ventricular Systolic and Diastolic Function During Doxorubicin Therapy: A Prospective Radionuclide Ventriculographic and Echocardiographic Study
Thirty adult lymphoma patients were studied prospectively with serial radionuclide ventriculography (RVG) and echocardiography (ECHO) to investigate whether changes in left ventricular (LV) diastolic function precede the impairment of LV systolic function during doxorubicin therapy. The patients received 8-10 cycles of CHOP to a cumulative doxorubicin dose of 400-500 mg/m2. RVG and ECHO were performed at baseline and after cumulative doxorubicin doses of 200, 400 and 500 mg/m2. Left ventricular ejection fraction (LVEF) decreased from 58 +/- 1.3 to 49.6 +/- 1.7% (p < 0.001) and from 58 +/- 1.7 to 52.5 +/- 1.3% (p = 0.036) as assessed with RVG and 2D ECHO, respectively. Of the diastolic ECHO doppler indices peak E wave velocity decreased from 63.3 +/- 3.2 to 51.3 +/- 2.6 cm/s (p = 0.008) and LV filling during the first 1/3 of diastole (1/3FF) from 42.2 +/- 1.7 to 36.5 +/- 2.0% (p < 0.001). The decrease in LVEF was statistically significant after the cumulative doxorubicin dose of 200 mg/m2 as assessed with RVG and after 400 mg/m2 as assessed with 2D ECHO. The decrease in 1/3FF reached the statistical significance after the cumulative doxorubicin dose of 400 mg/m2 and the decrease in peak E wave velocity after 500 mg/m2. This study shows that during doxorubicin therapy there are significant changes both in systolic and diastolic LV function. In addition, these changes manifest at relatively low cumulative doxorubicin doses and occur concomitantly. Thus, the assessment of diastolic function provides no advantage over monitoring systolic function during doxorubicin therapy.
- 1 January 2002
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 43 (9) , 1807-1811
Concomitant Impairment of Left Ventricular Systolic and Diastolic Function During Doxorubicin Therapy: A Prospective Radionuclide Ventriculographic and Echocardiographic Study
Thirty adult lymphoma patients were studied prospectively with serial radionuclide ventriculography (RVG) and echocardiography (ECHO) to investigate whether changes in left ventricular (LV) diastolic function precede the impairment of LV systolic function during doxorubicin therapy. The patients received 8-10 cycles of CHOP to a cumulative doxorubicin dose of 400-500 mg/m2. RVG and ECHO were performed at baseline and after cumulative doxorubicin doses of 200, 400 and 500 mg/m2. Left ventricular ejection fraction (LVEF) decreased from 58 +/- 1.3 to 49.6 +/- 1.7% (p < 0.001) and from 58 +/- 1.7 to 52.5 +/- 1.3% (p = 0.036) as assessed with RVG and 2D ECHO, respectively. Of the diastolic ECHO doppler indices peak E wave velocity decreased from 63.3 +/- 3.2 to 51.3 +/- 2.6 cm/s (p = 0.008) and LV filling during the first 1/3 of diastole (1/3FF) from 42.2 +/- 1.7 to 36.5 +/- 2.0% (p < 0.001). The decrease in LVEF was statistically significant after the cumulative doxorubicin dose of 200 mg/m2 as assessed with RVG and after 400 mg/m2 as assessed with 2D ECHO. The decrease in 1/3FF reached the statistical significance after the cumulative doxorubicin dose of 400 mg/m2 and the decrease in peak E wave velocity after 500 mg/m2. This study shows that during doxorubicin therapy there are significant changes both in systolic and diastolic LV function. In addition, these changes manifest at relatively low cumulative doxorubicin doses and occur concomitantly. Thus, the assessment of diastolic function provides no advantage over monitoring systolic function during doxorubicin therapy.
- 1 December 2001
- Vol. 101 (6) , 601-7
Neuroendocrine changes during the evolution of doxorubicin-induced left ventricular dysfunction in adult lymphoma patients.
Doxorubicin-induced cardiotoxicity was used as a model to prospectively investigate neuroendocrine changes during the development of left ventricular dysfunction. Radionuclide ventriculography, frequency domain analysis of heart rate variability (HRV), and plasma noradrenaline and natriuretic peptide measurements were performed in 27 adult lymphoma patients at baseline and after cumulative doxorubicin doses of 200, 400 and 500 mg/m(2). The left ventricular ejection fraction (LVEF) decreased from 58.1+/-1.4% to 50.3+/-1.1% (P<0.001) and 49.3+/-1.7% (P<0.001) after cumulative doxorubicin doses of 400 and 500 mg/m(2) respectively. With a doxorubicin dose of up to 400 mg/m(2) there was an increase in sympathetic tone, characterized by a decrease in the normalized high-frequency (HF(nu)) power (P=0.011), and increases in the normalized low-frequency (LF(nu)) power (P=0.011), the LF/HF ratio (P=0.021) and the plasma noradrenaline concentration (P=0.034). The decrease in LVEF was correlated with the changes in LF(nu) and HF(nu) power (r=0.540, P=0.012) and LF/HF ratio (r=-0.452, P=0.04). However, after the cumulative doxorubicin dose of 500 mg/m(2) the changes in HRV components and plasma noradrenaline levels returned towards baseline. This was accompanied by increased concentrations of plasma atrial natriuretic peptide (P=0.004) and brain natriuretic peptide (P=0.021). Our findings suggest that doxorubicin-induced left ventricular dysfunction is associated with an early change in sympathovagal balance towards sympathetic predominance. Along with further progression of left ventricular dysfunction, there is an attenuation of sympathetic tone, which may be attributable to sympatho-adrenal inhibition by increased secretion of natriuretic peptides.
- 1 December 2001
- Vol. 101 (6) , 601-7
Neuroendocrine changes during the evolution of doxorubicin-induced left ventricular dysfunction in adult lymphoma patients.
Doxorubicin-induced cardiotoxicity was used as a model to prospectively investigate neuroendocrine changes during the development of left ventricular dysfunction. Radionuclide ventriculography, frequency domain analysis of heart rate variability (HRV), and plasma noradrenaline and natriuretic peptide measurements were performed in 27 adult lymphoma patients at baseline and after cumulative doxorubicin doses of 200, 400 and 500 mg/m(2). The left ventricular ejection fraction (LVEF) decreased from 58.1+/-1.4% to 50.3+/-1.1% (P<0.001) and 49.3+/-1.7% (P<0.001) after cumulative doxorubicin doses of 400 and 500 mg/m(2) respectively. With a doxorubicin dose of up to 400 mg/m(2) there was an increase in sympathetic tone, characterized by a decrease in the normalized high-frequency (HF(nu)) power (P=0.011), and increases in the normalized low-frequency (LF(nu)) power (P=0.011), the LF/HF ratio (P=0.021) and the plasma noradrenaline concentration (P=0.034). The decrease in LVEF was correlated with the changes in LF(nu) and HF(nu) power (r=0.540, P=0.012) and LF/HF ratio (r=-0.452, P=0.04). However, after the cumulative doxorubicin dose of 500 mg/m(2) the changes in HRV components and plasma noradrenaline levels returned towards baseline. This was accompanied by increased concentrations of plasma atrial natriuretic peptide (P=0.004) and brain natriuretic peptide (P=0.021). Our findings suggest that doxorubicin-induced left ventricular dysfunction is associated with an early change in sympathovagal balance towards sympathetic predominance. Along with further progression of left ventricular dysfunction, there is an attenuation of sympathetic tone, which may be attributable to sympatho-adrenal inhibition by increased secretion of natriuretic peptides.
- 26 October 2001
- Published by Portland Press Ltd. in Clinical Science
- Vol. 101 (6) , 601-607
Neuroendocrine changes during the evolution of doxorubicin-induced left ventricular dysfunction in adult lymphoma patients
Doxorubicin-induced cardiotoxicity was used as a model to prospectively investigate neuroendocrine changes during the development of left ventricular dysfunction. Radionuclide ventriculography, frequency domain analysis of heart rate variability (HRV), and plasma noradrenaline and natriuretic peptide measurements were performed in 27 adult lymphoma patients at baseline and after cumulative doxorubicin doses of 200, 400 and 500mg/m2. The left ventricular ejection fraction (LVEF) decreased from 58.1±1.4% to 50.3±1.1% (P < 0.001) and 49.3±1.7% (P < 0.001) after cumulative doxorubicin doses of 400 and 500mg/m2 respectively. With a doxorubicin dose of up to 400mg/m2 there was an increase in sympathetic tone, characterized by a decrease in the normalized high-frequency (HFnu) power (P = 0.011), and increases in the normalized low-frequency (LFnu) power (P = 0.011), the LF/HF ratio (P = 0.021) and the plasma noradrenaline concentration (P = 0.034). The decrease in LVEF was correlated with the changes in LFnu and HFnu power (r = 0.540, P =0.012) and LF/HF ratio (r =-0.452, P =0.04). However, after the cumulative doxorubicin dose of 500mg/m2 the changes in HRV components and plasma noradrenaline levels returned towards baseline. This was accompanied by increased concentrations of plasma atrial natriuretic peptide (P = 0.004) and brain natriuretic peptide (P = 0.021). Our findings suggest that doxorubicin-induced left ventricular dysfunction is associated with an early change in sympathovagal balance towards sympathetic predominance. Along with further progression of left ventricular dysfunction, there is an attenuation of sympathetic tone, which may be attributable to sympatho-adrenal inhibition by increased secretion of natriuretic peptides.
- 26 October 2001
- Published by Portland Press Ltd. in Clinical Science
- Vol. 101 (6) , 601-607
Neuroendocrine changes during the evolution of doxorubicin-induced left ventricular dysfunction in adult lymphoma patients
Doxorubicin-induced cardiotoxicity was used as a model to prospectively investigate neuroendocrine changes during the development of left ventricular dysfunction. Radionuclide ventriculography, frequency domain analysis of heart rate variability (HRV), and plasma noradrenaline and natriuretic peptide measurements were performed in 27 adult lymphoma patients at baseline and after cumulative doxorubicin doses of 200, 400 and 500mg/m2. The left ventricular ejection fraction (LVEF) decreased from 58.1±1.4% to 50.3±1.1% (P < 0.001) and 49.3±1.7% (P < 0.001) after cumulative doxorubicin doses of 400 and 500mg/m2 respectively. With a doxorubicin dose of up to 400mg/m2 there was an increase in sympathetic tone, characterized by a decrease in the normalized high-frequency (HFnu) power (P = 0.011), and increases in the normalized low-frequency (LFnu) power (P = 0.011), the LF/HF ratio (P = 0.021) and the plasma noradrenaline concentration (P = 0.034). The decrease in LVEF was correlated with the changes in LFnu and HFnu power (r = 0.540, P =0.012) and LF/HF ratio (r =-0.452, P =0.04). However, after the cumulative doxorubicin dose of 500mg/m2 the changes in HRV components and plasma noradrenaline levels returned towards baseline. This was accompanied by increased concentrations of plasma atrial natriuretic peptide (P = 0.004) and brain natriuretic peptide (P = 0.021). Our findings suggest that doxorubicin-induced left ventricular dysfunction is associated with an early change in sympathovagal balance towards sympathetic predominance. Along with further progression of left ventricular dysfunction, there is an attenuation of sympathetic tone, which may be attributable to sympatho-adrenal inhibition by increased secretion of natriuretic peptides.
- Open Access
- 1 April 2001
- Published by Wiley in Journal of Internal Medicine
- Vol. 249 (4) , 297-303
Comparison of echocardiography and radionuclide ventriculography in the follow‐up of left ventricular systolic function in adult lymphoma patients during doxorubicin therapy
Nousiainen T, Vanninen E, Jantunen E, Puustinen J, Remes J, Rantala A, Hartikainen J (Kuopio University Hospital; Satakunta Central Hospital, Pori; Finland). Comparison of echocardiography and radionuclide ventriculography in the follow‐up of left ventricular systolic function in adult lymphoma patients during doxorubicin therapy (Original Article). J Intern Med 2001; 249: 297–303. Objectives. To compare echocardiography (ECHO) and radionuclide ventriculography (RVG) in the monitoring of left ventricular systolic function during doxorubicin therapy in adult lymphoma patients. Design. Prospective study. Settings. University hospital. Subjects. A total of 28 adult patients who received doxorubicin to a cumulative dose of 400–500 mg m–2. Main outcome measures. ECHO and RVG were performed at baseline and after cumulative doxorubicin doses of 200, 400 and 500 mg m–2. Results. At baseline, the mean (±SE) left ventricular ejection fractions (LVEF) were 58 ± 1.3, 71 ± 1.8 and 58 ± 1.7% as determined by RVG, M‐mode ECHO and two‐dimensional (2D) ECHO, respectively. After the cumulative doxorubicin dose of 500 mg m–2 LVEF decreased to 49.6 ± 1.7% (RVG) (P < 0.001), 62 ± 1.6% (M‐mode) (P=0.006) and 52.5 ± 1.3% (2D ECHO) (P=0.036). Although a significant correlation between LVEF determined by RVG and M‐mode ECHO (r=0.615, P=0.002) and a trend between RVG and 2D ECHO (r=0.364, P=0.096) were observed, there were substantial differences in the results of individual patients. In the agreement analysis using the method of Bland and Altman there was a mean difference of 12% units with the upper limit of agreement +26% units and the lower limit of agreement –2.1% units for LVEF determinations with M‐mode ECHO and RVG, and a mean difference of 3.3% units with upper and lower limits of agreement +19.6 and –13.1% units for LVEF determinations with 2D ECHO and RVG, respectively. Conclusion. We found only a moderate agreement between left ventricular systolic function determined by ECHO and RVG methods. Thus, in the follow‐up of left ventricular function in adult patients during doxorubicin therapy, the guidelines based on LVEF measurement by RVG cannot be applied to ECHO. Consequently, RVG remains the method of choice in this context.
- 1 April 2001
- Published by Wiley in Journal of Internal Medicine
- Vol. 249 (4) , 297-303
Open AccessComparison of echocardiography and radionuclide ventriculography in the follow‐up of left ventricular systolic function in adult lymphoma patients during doxorubicin therapy
Nousiainen T, Vanninen E, Jantunen E, Puustinen J, Remes J, Rantala A, Hartikainen J (Kuopio University Hospital; Satakunta Central Hospital, Pori; Finland). Comparison of echocardiography and radionuclide ventriculography in the follow‐up of left ventricular systolic function in adult lymphoma patients during doxorubicin therapy (Original Article). J Intern Med 2001; 249: 297–303. Objectives. To compare echocardiography (ECHO) and radionuclide ventriculography (RVG) in the monitoring of left ventricular systolic function during doxorubicin therapy in adult lymphoma patients. Design. Prospective study. Settings. University hospital. Subjects. A total of 28 adult patients who received doxorubicin to a cumulative dose of 400–500 mg m–2. Main outcome measures. ECHO and RVG were performed at baseline and after cumulative doxorubicin doses of 200, 400 and 500 mg m–2. Results. At baseline, the mean (±SE) left ventricular ejection fractions (LVEF) were 58 ± 1.3, 71 ± 1.8 and 58 ± 1.7% as determined by RVG, M‐mode ECHO and two‐dimensional (2D) ECHO, respectively. After the cumulative doxorubicin dose of 500 mg m–2 LVEF decreased to 49.6 ± 1.7% (RVG) (P < 0.001), 62 ± 1.6% (M‐mode) (P=0.006) and 52.5 ± 1.3% (2D ECHO) (P=0.036). Although a significant correlation between LVEF determined by RVG and M‐mode ECHO (r=0.615, P=0.002) and a trend between RVG and 2D ECHO (r=0.364, P=0.096) were observed, there were substantial differences in the results of individual patients. In the agreement analysis using the method of Bland and Altman there was a mean difference of 12% units with the upper limit of agreement +26% units and the lower limit of agreement –2.1% units for LVEF determinations with M‐mode ECHO and RVG, and a mean difference of 3.3% units with upper and lower limits of agreement +19.6 and –13.1% units for LVEF determinations with 2D ECHO and RVG, respectively. Conclusion. We found only a moderate agreement between left ventricular systolic function determined by ECHO and RVG methods. Thus, in the follow‐up of left ventricular function in adult patients during doxorubicin therapy, the guidelines based on LVEF measurement by RVG cannot be applied to ECHO. Consequently, RVG remains the method of choice in this context.